Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 6

Results: 33

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Published in:

2014

By:

Gopal, Ajay;
Tarantolo, Stefano;
Bellam, Naresh;
Green, Damian;
Griffin, Melissa;
Feldman, Tatyana;
Mato, Anthony;
Eisenfeld, Amy;
Stromatt, Scott;
Goy, Andre

Publication type:

Journal Article

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Published in:

2014

By:

Hong, D.;
Henary, H.;
Falchook, G.;
Naing, A.;
Fu, S.;
Moulder, S.;
Wheler, J.;
Tsimberidou, A.;
Durand, J.;
Khan, R.;
Yang, P.;
Johansen, M.;
Newman, R.;
Kurzrock, R.

Publication type:

Journal Article

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Published in:

2014

By:

Waterhouse, Dawn;
Sutherland, Brent;
Santos, Nancy;
Masin, Dana;
Osooly, Maryam;
Strutt, Dita;
Ostlund, Christina;
Anantha, Malathi;
Harasym, Natashia;
Manisali, Irina;
Wehbe, Mohamed;
Bally, Marcel;
Webb, Murray

Publication type:

Journal Article

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Published in:

2014

By:

Ruzsa, A.;
Sen, M.;
Evans, M.;
Lee, L.;
Hideghety, K.;
Rottey, S.;
Klimak, P.;
Holeckova, P.;
Fayette, J.;
Csoszi, T.;
Erfan, J.;
Forssmann, U.;
Goddemeier, T.;
Bexon, A.;
Nutting, C.

Publication type:

Journal Article

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1188, doi. 10.1007/s10637-014-0119-0

By:

Bahleda, Rastislav;
Sessa, Cristiana;
Conte, Gianluca;
Gianni, Luca;
Capri, Giuseppe;
Varga, Andrea;
Oprea, Corina;
Daglish, Byzance;
Hospitel, Marie;
Soria, Jean-Charles

Publication type:

Article

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1181, doi. 10.1007/s10637-014-0121-6

By:

Falchook, Gerald;
Kurzrock, Razelle;
Gouw, Launce;
Hong, David;
McGregor, Kimberly;
Zhou, Xiaofei;
Shi, Hongliang;
Fingert, Howard;
Sharma, Sunil

Publication type:

Article

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1285, doi. 10.1007/s10637-014-0122-5

By:

Zhao, Meng;
Pan, Xueliang;
Layman, Rachel;
Lustberg, Maryam;
Mrozek, Ewa;
Macrae, Erin;
Wesolowski, Robert;
Carothers, Sarah;
Puhalla, Shannon;
Shapiro, Charles;
Ramaswamy, Bhuvaneswari

Publication type:

Article

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1197, doi. 10.1007/s10637-014-0124-3

By:

Bowles, Daniel;
Senzer, Neil;
Hausman, Diana;
Peterson, Scott;
Vo, Alex;
Walker, Luke;
Cohen, Roger;
Jimeno, Antonio

Publication type:

Article

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1213, doi. 10.1007/s10637-014-0125-2

By:

Gopal, Ajay;
Tarantolo, Stefano;
Bellam, Naresh;
Green, Damian;
Griffin, Melissa;
Feldman, Tatyana;
Mato, Anthony;
Eisenfeld, Amy;
Stromatt, Scott;
Goy, Andre

Publication type:

Article

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1204, doi. 10.1007/s10637-014-0127-0

By:

Hong, D.;
Henary, H.;
Falchook, G.;
Naing, A.;
Fu, S.;
Moulder, S.;
Wheler, J.;
Tsimberidou, A.;
Durand, J.;
Khan, R.;
Yang, P.;
Johansen, M.;
Newman, R.;
Kurzrock, R.

Publication type:

Article

The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1295, doi. 10.1007/s10637-014-0128-z

By:

Tastekin, Didem;
Tambas, Makbule;
Kilic, Kemal;
Erturk, Kayhan;
Arslan, Deniz

Publication type:

Article

Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1301, doi. 10.1007/s10637-014-0135-0

By:

Renck, Daiana;
Santos, André;
Machado, Pablo;
Petersen, Guilherme;
Lopes, Tiago;
Santos, Diógenes;
Campos, Maria;
Basso, Luiz

Publication type:

Article

Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1063, doi. 10.1007/s10637-014-0136-z

By:

Israelsson, S.;
Sävneby, A.;
Ekström, J-O.;
Jonsson, N.;
Edman, K.;
Lindberg, A.

Publication type:

Article

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1053, doi. 10.1007/s10637-014-0137-y

By:

Kuete, Victor;
Sandjo, Louis;
Djeussi, Doriane;
Zeino, Maen;
Kwamou, Guy;
Ngadjui, Bonaventure;
Efferth, Thomas

Publication type:

Article

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1071, doi. 10.1007/s10637-014-0138-x

By:

Waterhouse, Dawn;
Sutherland, Brent;
Santos, Nancy;
Masin, Dana;
Osooly, Maryam;
Strutt, Dita;
Ostlund, Christina;
Anantha, Malathi;
Harasym, Natashia;
Manisali, Irina;
Wehbe, Mohamed;
Bally, Marcel;
Webb, Murray

Publication type:

Article

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1226, doi. 10.1007/s10637-014-0139-9

By:

Chu, Quincy;
Sangha, Randeep;
Hotte, Sebastien;
Sergenson, Gwen;
Schnell, David;
Chand, Vikram;
Hirte, Hal

Publication type:

Article

Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1113, doi. 10.1007/s10637-014-0140-3

By:

Russell, E.;
O'Sullivan, E.;
Miller, C.;
Stanicka, J.;
McCarthy, F.;
Cotter, T.

Publication type:

Article

Ibrutinib (Imbruvica) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1096, doi. 10.1007/s10637-014-0141-2

By:

Grabinski, Nicole;
Ewald, Florian

Publication type:

Article

'Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183'.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1083, doi. 10.1007/s10637-014-0143-0

By:

Marchetti, Serena;
Pluim, Dick;
Beijnen, Jos;
Mazzanti, Roberto;
Tellingen, Olaf;
Schellens, Jan

Publication type:

Article

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1105, doi. 10.1007/s10637-014-0144-z

By:

Kim, Sun-Hee;
Margalit, Ofer;
Katoh, Hiroshi;
Wang, Dingzhi;
Wu, Hong;
Xia, Dianren;
Holla, Vijaykumar;
Yang, Peiying;
DuBois, Raymond

Publication type:

Article

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1236, doi. 10.1007/s10637-014-0145-y

By:

Lockhart, A.;
Sundaram, Shankar;
Sarantopoulos, John;
Mita, Monica;
Wang-Gillam, Andrea;
Moseley, Jennifer;
Barber, Stephanie;
Lane, Alex;
Wack, Claudine;
Kassalow, Laurent;
Dedieu, Jean-François;
Mita, Alain

Publication type:

Article

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1311, doi. 10.1007/s10637-014-0146-x

By:

Woo, Hyun;
Ahn, Hee;
Lee, Ha;
Park, Inkeun;
Kim, Young;
Hong, Junshik;
Sym, Sun;
Park, Jinny;
Lee, Jae;
Shin, Dong;
Cho, Eun

Publication type:

Article

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1258, doi. 10.1007/s10637-014-0147-9

By:

Pili, Roberto;
Carducci, Michael;
Brown, Peter;
Hurwitz, Herbert

Publication type:

Article

A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1123, doi. 10.1007/s10637-014-0148-8

By:

Valtorta, Silvia;
Nicolini, Gabriella;
Tripodi, Farida;
Meregalli, Cristina;
Cavaletti, Guido;
Avezza, Federica;
Crippa, Luca;
Bertoli, Gloria;
Sanvito, Francesca;
Fusi, Paola;
Pagliarin, Roberto;
Orsini, Fulvia;
Moresco, Rosa;
Coccetti, Paola

Publication type:

Article

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1144, doi. 10.1007/s10637-014-0149-7

By:

Ewald, Florian;
Nörz, Dominik;
Grottke, Astrid;
Hofmann, Bianca;
Nashan, Björn;
Jücker, Manfred

Publication type:

Article

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1308, doi. 10.1007/s10637-014-0150-1

By:

Carbonnaux, Mélodie;
Molin, Yann;
Souquet, Pierre-Jean;
Tantin, Arnaud;
Lombard-Bohas, Catherine;
Walter, Thomas

Publication type:

Article

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1246, doi. 10.1007/s10637-014-0151-0

By:

Tannir, Nizar;
Forero-Torres, Andres;
Ramchandren, Radhakrishnan;
Pal, Sumanta;
Ansell, Stephen;
Infante, Jeffrey;
de Vos, Sven;
Hamlin, Paul;
Kim, Stella;
Whiting, Nancy;
Gartner, Elaina;
Zhao, Baiteng;
Thompson, John

Publication type:

Article

In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1134, doi. 10.1007/s10637-014-0152-z

By:

Kong, Dexin;
Yamori, Takao;
Yamazaki, Kanami;
Dan, Shingo

Publication type:

Article

AD-O53.2-a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1155, doi. 10.1007/s10637-014-0153-y

By:

Pieczykolan, Jerzy;
Kubiński, Konrad;
Masłyk, Maciej;
Pawlak, Sebastian;
Pieczykolan, Anna;
Rózga, Piotr;
Szymanik, Michał;
Gałązka, Marlena;
Teska-Kamińska, Małgorzata;
Żerek, Bartłomiej;
Bukato, Katarzyna;
Poleszak, Katarzyna;
Jaworski, Albert;
Strożek, Wojciech;
Świder, Robert;
Zieliński, Rafał

Publication type:

Article

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1167, doi. 10.1007/s10637-014-0158-6

By:

Sero, Valeria;
Tavanti, Elisa;
Vella, Serena;
Hattinger, Claudia;
Fanelli, Marilù;
Michelacci, Francesca;
Versteeg, Rogier;
Valsasina, Barbara;
Gudeman, Beth;
Picci, Piero;
Serra, Massimo

Publication type:

Article

A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1269, doi. 10.1007/s10637-014-0159-5

By:

Brana, Irene;
Ocana, Alberto;
Chen, Eric;
Razak, Albiruni;
Haines, Christine;
Lee, Carol;
Douglas, Sarah;
Wang, Lisa;
Siu, Lillian;
Tannock, Ian;
Bedard, Philippe

Publication type:

Article

Contributions from emerging transcriptomics technologies and computational strategies for drug discovery.

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1316, doi. 10.1007/s10637-014-0081-x

By:

Kadioglu, Onat;
Efferth, Thomas

Publication type:

Article

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Published in:

Investigational New Drugs, 2014, v. 32, n. 6, p. 1278, doi. 10.1007/s10637-014-0117-2

By:

Ruzsa, A.;
Sen, M.;
Evans, M.;
Lee, L.;
Hideghety, K.;
Rottey, S.;
Klimak, P.;
Holeckova, P.;
Fayette, J.;
Csoszi, T.;
Erfan, J.;
Forssmann, U.;
Goddemeier, T.;
Bexon, A.;
Nutting, C.

Publication type:

Article